Profile data is unavailable for this security.
About the company
Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
- Revenue in EUR (TTM)15.62m
- Net income in EUR-104.19m
- Incorporated2011
- Employees112.00
- LocationInventiva SA50 rue de Dijon, DaixDAIX 21121FranceFRA
- Phone+33 380447500
- Websitehttps://inventivapharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gensight Biologics SA | 804.00k | -20.11m | 40.81m | 11.00 | -- | -- | -- | 50.76 | -0.3537 | -0.3537 | 0.0123 | -0.2402 | 0.0507 | -- | 21.73 | 50,250.00 | -126.79 | -79.44 | -- | -144.54 | -- | -- | -2,501.00 | -1,036.27 | -- | -1,250.38 | -- | -- | -50.93 | -- | 5.09 | -- | -58.28 | -- |
| Abionyx Pharma SA | 4.86m | -3.36m | 43.52m | 61.00 | -- | 4.25 | -- | 8.96 | -0.1063 | -0.1063 | 0.1548 | 0.2934 | 0.3316 | 21.80 | 6.05 | 80,264.46 | -22.93 | -18.82 | -33.15 | -28.87 | 19.19 | 14.32 | -69.15 | -128.54 | 2.22 | -114.07 | 0.2513 | -- | -11.65 | 92.84 | 16.36 | -- | 41.40 | -- |
| Novacyt SA | 22.15m | -44.59m | 49.00m | 240.00 | -- | 0.5825 | -- | 2.21 | -0.6313 | -0.6361 | 0.3137 | 1.19 | 0.1603 | -3.66 | 1.02 | 82,046.80 | -32.27 | 10.94 | -38.44 | 14.49 | 153.78 | 61.98 | -201.27 | 17.64 | 3.82 | -159.39 | 0.1573 | -- | -44.97 | -0.9408 | -25.22 | -- | 2.09 | -- |
| Inventiva SA | 15.62m | -104.19m | 76.93m | 112.00 | -- | -- | -- | 4.93 | -2.08 | -2.08 | 0.3104 | -- | -- | -- | -- | 139,437.50 | -- | -54.30 | -- | -69.98 | -- | -- | -653.15 | -669.97 | -- | -- | -- | -- | 43.50 | 40.46 | -103.46 | -- | -0.33 | -- |
| Adocia SA | 2.15m | -21.16m | 81.11m | 78.00 | -- | -- | -- | 37.73 | -1.93 | -1.93 | 0.194 | -0.4908 | 0.0774 | 2.62 | 7.44 | 27,564.10 | -76.16 | -43.08 | -396.14 | -72.93 | 7.91 | -- | -984.28 | -514.53 | 1.01 | -2.07 | 2.12 | -- | -81.22 | -46.13 | -206.65 | -- | -27.60 | -- |
| Maat Pharma SA | 2.57m | -24.14m | 102.44m | 50.00 | -- | 4.00 | -- | 39.84 | -2.03 | -2.03 | 0.2161 | 1.84 | 0.0511 | 6.50 | 2.18 | 51,420.00 | -47.94 | -35.49 | -64.64 | -42.98 | 67.87 | -- | -938.86 | -1,157.54 | 2.75 | -47.95 | 0.4014 | -- | 55.80 | -- | -43.78 | -- | 30.30 | -- |
| Eurofins-Cerep SA | 42.42m | 7.25m | 109.96m | 218.00 | 15.16 | 1.63 | 11.89 | 2.59 | 1,438.10 | 1,438.10 | 8,415.76 | 13,378.57 | 0.5618 | 1.52 | 5.41 | 186,032.70 | 9.61 | 14.21 | 11.08 | 17.51 | 85.48 | 73.61 | 17.10 | 19.77 | 6.89 | -- | 0.0047 | -- | -7.47 | 11.60 | -33.72 | 14.64 | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 17 Jul 2024 | 7.86m | 14.98% |
| Qatar Investment Authority (Investment Management)as of 01 Mar 2024 | 5.16m | 9.83% |
| Yiheng Capital Management LPas of 01 Mar 2024 | 3.85m | 7.33% |
| Amundi Asset Management SA (Investment Management)as of 28 Jun 2024 | 138.25k | 0.26% |
| UBS LA MAISON de Gestionas of 30 Dec 2022 | 37.50k | 0.07% |
| BG Fund Management Luxembourg SAas of 31 Dec 2023 | 29.78k | 0.06% |
| Financi�re Arbevel SAas of 30 Dec 2022 | 21.00k | 0.04% |
| Crossinvest SAas of 31 Dec 2023 | 7.49k | 0.01% |
| CAPFI DELEN Asset Management NVas of 31 Mar 2023 | 2.00k | 0.00% |
| Friedland Gestion SASas of 26 Apr 2024 | 1.00k | 0.00% |
